1615P Health-related quality of life in the phase III NADINA trial: Neoadjuvant vs adjuvant checkpoint blockade in stage III melanoma

Maarten Egeler; Judith Lijnsvelt; M.W. Lucas; Victoria Atkinson; Muhammad A. Khattak; Miles C. Andrews; M. Boers-Sonderen; Geke A.P. Hospers; M.S. Carlino; Jan Willem de Groot; M. Stevense-den Boer; E. Kapiteijn; K. Suijkerbuijk; P. Rutkowski; A.M. Menzies; Shahneen Sandhu; Astrid A.M. van der Veldt; G.V. Long; C.U. Blank; Lonneke V. van de Poll‐Franse

doi:10.1016/j.annonc.2025.08.2243

Related publications

Article2025

1618P Return to work in the phase III trial NADINA: Neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients

Judith Lijnsvelt, Maarten Egeler, M.W. Lucas, A.M. Menzies, Rachael L. Morton, Astrid A.M. van der Veldt, P. Rutkowski, E. Kapiteijn, Shahneen Sandhu, K. Suijkerbuijk, Jan Willem de Groot, M.S. Carlino, G. Hospers, F. Van Den Eertwegh, M. Boers-Sonderen, Miles C. Andrews, Victoria Atkinson, G.V. Long, Christian U. Blank, Lonneke V. van de Poll‐Franse

Article2024

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta López‐Yurda, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, Alex Torres Acosta, Serigne Lo, Geke A.P. Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long

Article2024

Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.

Minke W. Lucas, Reetta Arokoski, Alexander M. Menzies, Saskia Pulleman, Robyn P.M. Saw, Winan J. van Houdt, Mark B. Faries, Caroline Robert, Paolo A. Ascierto, Célèste Lebbé, Matteo S. Carlino, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long, Christian U. Blank, Lonneke V. van de Poll‐Franse, Judith Lijnsvelt

Article2024

LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial

M.W. Lucas, A.M. Menzies, Marta López‐Yurda, Richard A. Scolyer, B. van de Wiel, R.P.M. Saw, W. Van Houdt, Nigel Maher, A. Torres Acosta, M. Boers-Sonderen, G. Hospers, M.S. Carlino, Jan Willem de Groot, E. Kapiteijn, K. Suijkerbuijk, P. Rutkowski, Shahneen Sandhu, Astrid A.M. van der Veldt, G.V. Long, C.U. Blank

Article2021

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, James Larkin, Paul Lorigan, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra,

1615P Health-related quality of life in the phase III NADINA trial: Neoadjuvant vs adjuvant checkpoint blockade in stage III melanoma

Discussion(0)

Related publications

1618P Return to work in the phase III trial NADINA: Neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.

LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial